 Applied Genetic Technologies Corporation AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare diseases, today provided an update on the continued productivity and quality improvements made in its proprietary manufacturing platform that is currently being used to create clinical trial material for the Companys planned pivotal clinical trials in X-linked retinitis pigmentosa XLRP. Continuous improvements to our proprietary HSV-based manufacturing process have been a critical AGTC objective for more than a decade, and our efforts have resulted in AAV vector quality and yields that we believe exceed the performance and economics of other currently available approaches to produce AAV gene therapy products, particularly those using adherent cell platforms, said Dr. Dave Knop, PhD, Head of Process Development at AGTC. 